ERBB2 and breast cancer: The molecular subtypes of breast cancer of the study population (n = 128, there was some missing data) included luminal A 71.1% (n = 91 out of 128), luminal B/HER2-positive 15.6% (n = 20), luminal B/HER2-negative 6.3% (n = 8), HER2-enriched 4.7% (n = 6), and triple-negative 2.3% (n = 3).